57 research outputs found
One-carbon metabolism in cancer
Cells require one-carbon units for nucleotide synthesis, methylation and reductive metabolism, and these pathways support the high proliferative rate of cancer cells. As such, anti-folates, drugs that target one-carbon metabolism, have long been used in the treatment of cancer. Amino acids, such as serine are a major one-carbon source, and cancer cells are particularly susceptible to deprivation of one-carbon units by serine restriction or inhibition of de novo serine synthesis. Recent work has also begun to decipher the specific pathways and sub-cellular compartments that are important for one-carbon metabolism in cancer cells. In this review we summarise the historical understanding of one-carbon metabolism in cancer, describe the recent findings regarding the generation and usage of one-carbon units and explore possible future therapeutics that could exploit the dependency of cancer cells on one-carbon metabolism
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notablesuccesses in some cancers; however, significant problems remain with this approach. Many targetedtherapies are highly toxic, costs are extremely high, and most patients experience relapse after a fewdisease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistantimmortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are notreliant upon the same mechanisms as those which have been targeted). To address these limitations, aninternational task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspectsof relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a widerange of high-priority targets (74 in total) that could be modified to improve patient outcomes. For thesetargets, corresponding low-toxicity therapeutic approaches were then suggested, many of which werephytochemicals. Proposed actions on each target and all of the approaches were further reviewed forknown effects on other hallmark areas and the tumor microenvironment. Potential contrary or procar-cinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixedevidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of therelationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. Thisnovel approach has potential to be relatively inexpensive, it should help us address stages and types ofcancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for futureresearch is offered
Computational approaches for understanding one-carbon metabolism in cancer
Cancer metabolism is an emerging research area in cancer biology and therapeutics. One of the major metabolic pathways known to play important roles in the pathogenesis of cancer is one-carbon (1-C) metabolism. 1-C metabolism integrates the status of many dietary nutrients as inputs, and in turn regulates a variety of cellular processes including de novo nucleotide synthesis, lipid metabolism, protein biosynthesis, redox metabolism, transsulfuration, and epigenetics. As the regulation of these cellular processes is critical to cells, the tuning of the activity of 1-C metabolism plays important roles in cancer. Previous studies have established implications of genetic and dietary perturbations of multiple components of 1-C metabolism in human cancers. However, the heterogeneity among cancer types and subtypes with respect to the usage and flux distribution of 1-C metabolism has not been systematically quantified. There remain great potentials in deciphering how 1-C metabolism plays different roles in different human cancers, especially since this metabolic pathway is targeted by a number of the existing antimetabolite chemotherapeutic agents.
In this dissertation, I quantitatively characterize various aspects of 1-C metabolism across human cancers. I first investigate the between-cancer-type variation in the usage of serine by 1-C metabolism using flux distribution analyses and find substantial heterogeneity. I also show that a common feature across cancers is correlated activation of nucleotide and redox metabolism. Next I assess the link between 1-C metabolism and DNA methylation using computational modeling and machine-learning. I find significant contribution from particular enzymes within 1-C metabolism— such as methionine adenosyltransferases— in explaining the within- cancer-type (inter-individual) variation in DNA methylation. My results provide evidence that misregulation of 1-C metabolism is at least in part responsible for disrupted DNA methylation profiles in tumors leading to epigenetic instability and higher malignancy. Given evidence for the role of 1-C metabolism and the methionine cycle in methylation dynamics, I next evaluate the potential for dietary intervention using the amino acid methionine. To this end, I model human serum methionine levels and quantify the contribution of various factors in determining the concentration of methionine. I discover that dietary factors could together explain nearly 30% of overall variation in methionine concentrations, and also provide evidence that the relationship between 1-C metabolism and methylation exists at physiological concentrations of methionine. Finally, I use a novel approach to identify gene expression markers of tumor response to 5-FU and Gemcitabine —two of the commonly used antimetabolite chemotherapies that target enzymes in 1-C metabolism. I discover that response to these agents is to a large degree determined by the metabolic state of tumors and the expression levels of specific target pathways of each of these agents. Together, my findings provide quantitative information about the heterogeneity among tumors with respect to the usage of 1-C metabolism, and delineate some of the ways this information can be translated into clinical decision- making
Molecular features that predict the response to antimetabolite chemotherapies
Abstract Background Antimetabolite chemotherapeutic agents that target cellular metabolism are widely used in the clinic and are thought to exert their anti-cancer effects mainly through non-specific cytotoxic effects. However, patients vary dramatically with respect to treatment outcome, and the sources of heterogeneity remain largely unknown. Methods Here, we introduce a computational method for identifying gene expression signatures of response to chemotherapies and apply it to human tumors and cancer cell lines. Furthermore, we characterize a set of 17 antimetabolite agents in various contexts to investigate determinants of sensitivity to these agents. Results We identify distinct favorable and unfavorable metabolic expression signatures for 5-FU and Gemcitabine. Importantly, we find that metabolic pathways targeted by each of these antimetabolites are specifically enriched in its expression signatures. We provide evidence against the common notion about non-specific cytotoxic functions of antimetabolite drugs. Conclusions This study demonstrates through unbiased analyses that the activities of metabolic pathways likely contribute to therapeutic response
Characterization of the Usage of the Serine Metabolic Network in Human Cancer
The serine, glycine, one-carbon (SGOC) metabolic network is implicated in cancer pathogenesis, but its general functions are unknown. We carried out a computational reconstruction of the SGOC network and then characterized its expression across thousands of cancer tissues. Pathways including methylation and redox metabolism exhibited heterogeneous expression indicating a strong context dependency of their usage in tumors. From an analysis of coexpression, simultaneous up- or downregulation of nucleotide synthesis, NADPH, and glutathione synthesis was found to be a common occurrence in all cancers. Finally, we developed a method to trace the metabolic fate of serine using stable isotopes, high-resolution mass spectrometry, and a mathematical model. Although the expression of single genes didn’t appear indicative of flux, the collective expression of several genes in a given pathway allowed for successful flux prediction. Altogether, these findings identify expansive and heterogeneous functions for the SGOC metabolic network in human cancer
esalat
به کارگیری رویکرد معیوب در ارزشیابی تربیت دینی میتواند به صدمه ای جبرانناپذیر بر پیکرة تربیتدینی و انحراف جدی آن از اهداف قصد شده منجر شود. مسئله اساسی این پژوهش آن است کهرویکرد ارزشیابی نتیجهمحور رایج در تربیت دینی، با نظر به آیات قرآن مجید و دلایل عقلی تا چه حددرست است وچه جایگزینی برای آن وجود دارد. در این پژوهش علاوه بر استدلال های عقلی برگرفتهاز متون مرتبط، برخی آیات قرآن مجید به عنوان سند متقن و اصیل اسلام با روش تحلیل محتوای کیفیدستهبندی و واکاوی شد. چهار دسته از آیات قرآن کریم و برخی دلایل عقلی، نشان میدهند که به طورکلی و بدون در نظر گرفتن موارد خاص، ارزشیابی نتیجهمحور از تربیت دینی با روح دین و هدف ازتربیت دینی ناسازگار است . نتیجه آنکه ارزشیابی در نظام تربیت دینی باید از سنجش نتایج(نتیجهمحوری) به سمت ارزیابی فرایندها (فرآیندمحوری) معطوف گردد. ارزشیابی فرایندمحور نیز بهمعنی بررسی و مراقبت از سلامت حرکت فرایند یاددهی یادگیری در مسیر صحیح تربیت دینی و نهبررسی فرایند نیل به نتیجه قصد شده درنظر گرفته شود
A novel approach toward optimal workflow selection for DNA methylation biomarker discovery
Abstract DNA methylation is a major epigenetic modification involved in many physiological processes. Normal methylation patterns are disrupted in many diseases and methylation-based biomarkers have shown promise in several contexts. Marker discovery typically involves the analysis of publicly available DNA methylation data from high-throughput assays. Numerous methods for identification of differentially methylated biomarkers have been developed, making the need for best practices guidelines and context-specific analyses workflows exceedingly high. To this end, here we propose TASA, a novel method for simulating methylation array data in various scenarios. We then comprehensively assess different data analysis workflows using real and simulated data and suggest optimal start-to-finish analysis workflows. Our study demonstrates that the choice of analysis pipeline for DNA methylation-based marker discovery is crucial and different across different contexts
Additional file 1: of Molecular features that predict the response to antimetabolite chemotherapies
Supplementary Figures. Figure S1. Relationship between target enzyme expression and response to Gemcitabine in TCGA pancreatic cancer. A) Kaplan-Meier plot compares progression free survival in high-RRM1 expression vs. low-RRM1 expression subgroups of TCGA PAAD patients. B) Kaplan-Meier plot compares progression free survival in high-RRM2 expression vs. low-RRM2 expression subgroups TCGA PAAD patients. Figure S2. Relationship between target enzyme expression and survival in an independent pancreatic cancer cohort. A) Kaplan-Meier plot compares overall survival in high-RRM1 expression vs. low-RRM1 expression subgroups of patients. B) Kaplan-Meier plot compares overall survival in high-RRM2 expression vs. low-RRM2 expression subgroups of patients. C) Kaplan-Meier plot compares overall survival in subgroups of patients divided based on our gene signature (see Methods). Figure S3. Identifying gene expression signatures of sensitivity to Gemcitabine in pancreatic cancer cell lines. A) Schematic of the step-wise filtering used for gene selection in pancreatic cancer (COSMIC PAAD). B) Hierarchical clustering heatmap of the discretized gene favorability scores. Columns represent genes and rows represent individuals. Favorable scores are shown by the color red (F=1), unfavorable by blue (F= -1), and neutral by yellow (F=0) (see Methods). C) Box-plots comparing the resistance to Gemcitabine (log IC-50 values) between the two cell line subgroups identified in part B (error bars show the range of the data points in each group). (DOCX 225Â kb
Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow
Antimetabolites that affect nucleotide metabolism are frontline chemotherapy agents in several cancers and often successfully target one carbon metabolism. However, the precise mechanisms and resulting determinants of their therapeutic value are unknown. We show that 5-fluorouracil (5-FU), a commonly used antimetabolite therapeutic with varying efficacy, induces specific alterations to nucleotide metabolism by disrupting pyrimidine homeostasis. An integrative metabolomics analysis of the cellular response to 5-FU reveals intracellular uracil accumulation, whereas deoxyuridine levels exhibited increased flux into the extracellular space, resulting in an induction of overflow metabolism. Subsequent analysis from mice bearing colorectal tumors treated with 5-FU show specific secretion of metabolites in tumor-bearing mice into serum that results from alterations in nucleotide flux and reduction in overflow metabolism. Together, these findings identify a determinant of an antimetabolite response that may be exploited to more precisely define the tumors that could respond to targeting cancer metabolism
Designing environmental literacy curriculum for secondary school education system in Iran: Using an integrated approach
- …